Cardiac core lab provisioning clinical trials on six continents during first half of 2006
Bethesda, MD– Cardiocore Lab, Inc., a premier provider of centralized cardiac safety monitoring and analysis, announced the launch of Cardiocore Limited. The company’s European operation, located in central London, provides project management, customer support and site provisioning services for Cardiocore’s European customers and for international trials sponsored by US-based clients.
“We are delighted to formally expand our operations into Europe,” said Cardiocore CEO, Jennifer Cotteleer. “High customer satisfaction has made Cardiocore the fastest growing cardiac core lab in the world. As we engage with clients and investigative sites around the globe, we remain by their side, always offering the prompt and professional care they have come to rely upon from Cardiocore.”
In 2006, Cardiocore is provisioning equipment and supplies for clinical trial sites in 12 time zones throughout North, South and Central America, Western and Eastern Europe, South Africa, the Middle East, the Pacific Rim, Australia and New Zealand. Sites in all countries access local language assistance through Cardiocore’s 24/7/365 telephonic site support services.
“The new European facility compliments our US headquarters which is positioned near the regulatory agencies in Washington, DC,” added Cardiocore COO, Scott Satin. “A central London location was selected for easy access to and from our European customers. Staffed by experienced project management and customer care professionals, the European operation will provide even greater hands-on services for Thorough QT, Phase I, II and III trials worldwide.”
|
| About Cardiocore: Cardiocore has provided superior centralized cardiac testing services to the pharmaceutical industry for 16 years. Services include centralized electrocardiography (ECG), Holter, echocardiography (ECHO), multigated acquisition scans (MUGA), and consulting services such as protocol development, scientific reporting and statistical analyses. The company is experienced in the design and the implementation of cardiac safety and efficacy testing in Phase I-IV and Thorough QT clinical trials. These services are supported by the company’s advanced data management system featuring the proprietary HolterGateway™ and CardioPortal™. Cardiocore’s U.S. headquarters is located in Bethesda, Maryland, its West Coast office is located in San Francisco, California, and its European subsidiary, Cardiocore Limited, is located in London, England. www.cardiocore.com |
